Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Wockhardt Generics Company Intelligence Report
Management Report
Published: March 2009
Pages: 16
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 195.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
The Indian company, Wockhardt Limited, was founded nearly four decades ago, and today claims its place amongst the country's top research and technology oriented pharmaceutical companies.
The company has subsidiaries in the United States, the United Kingdom and Brazil, and majority-owned companies in South Africa and Mexico. The company also has marketing offices in Africa, Russia, Central Asia and South East Asia.
In October 2007, Wockhardt acquired the US firm, Morton Grove Pharmaceuticals. The acquisition would more than double Wockhardt’s US portfolio, adding 31 products to the firm’s existing 23 marketed in the country.
In 2003, the company launched Wosulin, a recombinant insulin product. In doing so, Wockhardt became the fourth company, and first Asian manufacturer, to be able to offer the product. Wockhardt has identified biopharmaceuticals as a major developing market area, and is making plans to sell generic biopharmaceuticals in the US and EU once regulatory pathways have been established.
Wockhardt’s consolidated sales for 2007 were worth Rs26,642 million (US$645.5 million), an increase of 52.4% over figures for 2006. US and Western European revenues grew by 90.9% to be worth Rs16,813.5 million (US$407.4 million).
The company has subsidiaries in the United States, the United Kingdom and Brazil, and majority-owned companies in South Africa and Mexico. The company also has marketing offices in Africa, Russia, Central Asia and South East Asia.
In October 2007, Wockhardt acquired the US firm, Morton Grove Pharmaceuticals. The acquisition would more than double Wockhardt’s US portfolio, adding 31 products to the firm’s existing 23 marketed in the country.
In 2003, the company launched Wosulin, a recombinant insulin product. In doing so, Wockhardt became the fourth company, and first Asian manufacturer, to be able to offer the product. Wockhardt has identified biopharmaceuticals as a major developing market area, and is making plans to sell generic biopharmaceuticals in the US and EU once regulatory pathways have been established.
Wockhardt’s consolidated sales for 2007 were worth Rs26,642 million (US$645.5 million), an increase of 52.4% over figures for 2006. US and Western European revenues grew by 90.9% to be worth Rs16,813.5 million (US$407.4 million).